Literature DB >> 32910376

The In Vitro M1/M2 Polarization of Macrophages of BCG-Infected Mice.

D A Il'in1, V A Shkurupy2,3.   

Abstract

Cultured peritoneal macrophages from intact (control) and BCG-infected (experiment) male BALB/c mice were studied 90 days after infection. Polarization of macrophages by M1 (expression of GM-CSF, IFNγ, and CD16/32) and M2 (expression of bFGF and CD36) differentiation pathways was studied with consideration for their the nuclearity class. Mononuclear cells predominated (90% and higher) in macrophage cultures of both groups and presumably, were presented by mainly epithelioid cells. The results indicated polarization of mononuclear and multinuclear macrophages in the M2 direction under conditions of BCG granulomatosis and a higher initial M2 polarization of binuclear macrophages. In control cultures, the ratio of M2 to M1 macrophages was 0.57, in experimental cultures this ratio was 1.6. It seems that long persistence of Mycobacterium tuberculosis in macrophages served as a factor stimulating the plastic processes and transformation of macrophages into epithelioid cells that form the "core" of granulomas and their enlargement upon incorporation of macrophages.

Entities:  

Keywords:  BCG vaccine Mycobacteria; M1/M2 polarization of macrophages; macrophages

Mesh:

Substances:

Year:  2020        PMID: 32910376     DOI: 10.1007/s10517-020-04910-w

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  Content of the Major Extracellular Matrix Components of the Liver and Lungs in Mice with Chronic BCG-Granulomatosis Treated with Liposome-Encapsulated Dextrazide.

Authors:  L B Kim; A N Putyatina; G S Russkikh; V A Shkurupy
Journal:  Bull Exp Biol Med       Date:  2021-03-16       Impact factor: 0.804

2.  Destructive Processes and Fibrotic Complications in the Liver of Mice with BSG-Induced Granulomatosis Treated with Anti-Tuberculous Drugs.

Authors:  V A Shkurupy; A M Sinyavskaya; A V Troitskii
Journal:  Bull Exp Biol Med       Date:  2021-03-13       Impact factor: 0.804

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.